{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:37:41Z","timestamp":1787639861554,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,8,26]],"date-time":"2012-08-26T00:00:00Z","timestamp":1345939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s10067-012-2059-4","type":"journal-article","created":{"date-parts":[[2012,8,25]],"date-time":"2012-08-25T04:20:30Z","timestamp":1345868430000},"page":"1605-1610","source":"Crossref","is-referenced-by-count":9,"title":["A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis"],"prefix":"10.1007","volume":"31","author":[{"given":"J. D.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Zarabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. R.","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Valeriano-Marcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. B.","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Sebba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,26]]},"reference":[{"key":"2059_CR1","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"J Edwards","year":"2004","unstructured":"Edwards J, Szczepanski L, Szechinski J, Filiowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T (2004) Efficacy B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"issue":"5","key":"2059_CR2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filiowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz J, van Vollenhoven R, Li N, Agarwal S, Hessey E, Shaw T (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390\u20131400","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2059_CR3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"2059_CR4","unstructured":"Rituxan [package insert] (2011). Biogen Idec, Inc. and Genentech, Inc., South San Francisco; April 2011."},{"key":"2059_CR5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0091270003258651","volume":"43","author":"DE Mager","year":"2003","unstructured":"Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ (2003) Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharm 43:1216\u20131227","journal-title":"J Clin Pharm"},{"issue":"4","key":"2059_CR6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.94.4.723","volume":"94","author":"S Jonsson","year":"1988","unstructured":"Jonsson S, Kjartansson G, Gislason D, Helgason H (1988) Comparison of the oral and intravenous routes for treating asthma with methylprednisolone and theophylline. Chest 94(4):723\u2013726","journal-title":"Chest"},{"issue":"3","key":"2059_CR7","first-page":"169","volume":"42","author":"KM Lee","year":"2001","unstructured":"Lee KM, Lin YZ, Huang FY (2001) Steroid-induced acute psychosis in a child with asthma: report of one case. Acta Paediatr Taiwan 42(3):169\u2013171","journal-title":"Acta Paediatr Taiwan"},{"issue":"10","key":"2059_CR8","first-page":"1995","volume":"25","author":"MS Klein-Gitelman","year":"1998","unstructured":"Klein-Gitelman MS, Pachman LM (1998) Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol 25(10):1995\u20132002","journal-title":"J Rheumatol"},{"issue":"16","key":"2059_CR9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1001\/jama.1993.03500160080036","volume":"269","author":"GA Chrousos","year":"1993","unstructured":"Chrousos GA, Kattah JC, Beck RW, Cleary PA (1993) Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 269(16):2110\u20132112","journal-title":"JAMA"},{"issue":"3","key":"2059_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/rheumatology\/27.3.211","volume":"27","author":"ME Shipley","year":"1988","unstructured":"Shipley ME, Bacon PA, Berry H, Hazleman BL, Sturrock RD, Swinson DR, Williams IA (1988) Pulsed methylprednisolone in active early rheumatoid disease: a dose-ranging study. Br J Rheumatol 27(3):211\u2013214","journal-title":"Br J Rheumatol"},{"issue":"12","key":"2059_CR11","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/ard.2005.038349","volume":"65","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J (2006) A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 65(12):1578\u20131584","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2059_CR12","first-page":"CD007649","volume":"16","author":"V Ruiz Garcia","year":"2011","unstructured":"Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, G\u00e1lvez Mu\u00f1oz JG, Saiz Cuenca ES, Fry-Smith A (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 16(2):CD007649","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2059-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-012-2059-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2059-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:57:21Z","timestamp":1559105841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-012-2059-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,26]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["2059"],"URL":"https:\/\/doi.org\/10.1007\/s10067-012-2059-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,26]]}}}